Human interferon- and interferon- exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R

Journal of Biological Chemistry

Volumn 293, Issue 41, 2018, Pages 16057-16068

  Harris, Bethany D ^a   Schreiter, Jessica ^b   Chevrier, Marc ^b   Jordan, Jarrat L ^b   Walter, Mark R ^a  

^a University of Alabama at Birmingham   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BINDING ENERGY; CELL MEMBRANES;

BINDING AFFINITIES; BIOPHYSICAL PROPERTIES; CELL SURFACES; CELLULAR ASSAYS; FUNCTIONAL PROPERTIES; MUCOSAL SURFACE; RECEPTOR COMPLEX; TYPE I INTERFERONS;

GLYCOPROTEINS;

ALPHA BETA INTERFERON RECEPTOR; ALPHA BETA INTERFERON RECEPTOR 1; ALPHA BETA INTERFERON RECEPTOR 2; ALPHA2 INTERFERON; B18R PROTEIN; INTERFERON EPSILON; INTERFERON KAPPA; INTERFERON OMEGA; INTERFERON STIMULATED GENE FACTOR 3; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG; VIRAL PROTEIN; B18R PROTEIN, VACCINIA VIRUS; IFNAR1 PROTEIN, HUMAN; IFNAR2 PROTEIN, HUMAN; INTERFERON; INTERFERON-EPSILON, HUMAN; PROTEIN BINDING;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL SURFACE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; EC50; HUMAN; IMMUNE EVASION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TISSUE SPECIFICITY; VIRUS NEUTRALIZATION; CELL LINE; CHEMISTRY; GENE EXPRESSION; GENETICS; METABOLISM; MOLECULAR MODEL; MUTATION; VACCINIA VIRUS;

CELL LINE; GENE EXPRESSION; HUMANS; INTERFERON TYPE I; INTERFERONS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; RECEPTOR, INTERFERON ALPHA-BETA; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 85054890666     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.RA118.003617     Document Type: Article

References (54)

1. Samuel, C. E. (2001) Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778 – 809, table of contents CrossRef Medline
2. Ivashkiv, L. B., and Donlin, L. T. (2014) Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36 – 49 CrossRef Medline
3. Pestka, S., Langer, J. A., Zoon, K. C., and Samuel, C. E. (1987) Interferons and their actions. Annu. Rev. Biochem. 56, 727–777 CrossRef Medline
4. Pfeffer, L. M., Dinarello, C. A., Herberman, R. B., Williams, B. R., Borden, E. C., Bordens, R., Walter, M. R., Nagabhushan, T. L., Trotta, P. P., and Pestka, S. (1998) Biological properties of recombinant -interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58, 2489 –2499 Medline
5. Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster,G.R.,and Stark,G.R.(2007) Interferon satage50 :past, currentand future impact on biomedicine. Nat. Rev. Drug Discov. 6, 975–990 Cross Ref Medline
6. Der, S. D., Zhou, A., Williams, B. R., and Silverman, R. H. (1998) Identification of genes differentially regulated by interferon , , or using oligo-nucleotide arrays. Proc. Natl. Acad. Sci. U.S.A. 95, 15623–15628 CrossRef Medline
7. Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., and Rice, C. M. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481– 485 CrossRef Medline
8. Yang, C. H., Wei, L., Pfeffer, S. R., Du, Z., Murti, A., Valentine, W. J., Zheng, Y., and Pfeffer, L. M. (2007) Identification of CXCL11 as a STAT3-dependent gene induced by IFN. J. Immunol. 178, 986 –992 CrossRef Medline
9. Gray, R. C., Kuchtey, J., and Harding, C. V. (2007) CpG-B ODNs potently induce low levels of IFN- and induce IFN--dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J. Leukoc. Biol. 81, 1075–1085 Medline
10. Loh, J. E., Chang, C. H., Fodor, W. L., and Flavell, R. A. (1992) Dissection of the interferon -MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component(s). EMBO J. 11, 1351–1363 CrossRef Medline
11. Zhao, W., Cha, E. N., Lee, C., Park, C. Y., and Schindler, C. (2007) Stat2-dependent regulation of MHC class II expression. J. Immunol. 179, 463– 471 CrossRef Medline
12. Chawla-Sarkar, M., Lindner, D. J., Liu, Y. F., Williams, B. R., Sen, G. C., Silverman, R. H., and Borden, E. C. (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237–249 CrossRef
13. Herzer, K., Hofmann, T. G., Teufel, A., Schimanski, C. C., Moehler, M., Kanzler, S., Schulze-Bergkamen, H., and Galle, P. R. (2009) IFN--induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 69, 855– 862 CrossRef Medline
14. de Goër de Herve, M. G., Durali, D., Dembele, B., Giuliani, M., Tran, T. A., Azzarone, B., Eid, P., Tardieu, M., Delfraissy, J. F., and Taoufik, Y. (2011) Interferon- triggers B cell effector 1 (Be1) commitment. PLoS ONE 6, e19366 CrossRef Medline
15. Liu, Y., Carlsson, R., Comabella, M., Wang, J., Kosicki, M., Carrion, B., Hasan, M., Wu, X., Montalban, X., Dziegiel, M. H., Sellebjerg, F., Sørensen, P. S., Helin, K., and Issazadeh-Navikas, S. (2014) FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat. Med. 20, 272–282 CrossRef Medline
16. Delgoffe, G. M., and Vignali, D. A. (2014) A Fox of a different color: FoxA1 programs a new regulatory T cell subset. Nat. Med. 20, 236 –237 CrossRef Medline
17. Foster, G. R. (2010) Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginter-feron--2a and peginterferon--2b. Drugs 70, 147–165 Medline
18. Kirkwood, J. (2002) Cancer immunotherapy: the interferon-alpha experience. Semin. Oncol. 29, 18 –26 CrossRef Medline
19. Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., Alam, J. J., Bartoszak, D. M., Bourdette, D. N., Braiman, J., Brownscheidle, C. M., et al. (1996) Intramuscular interferon -1a for disease progression in relapsing multiple sclerosis: the multiple sclerosis collaborative research group (MSCRG). Ann. Neurol. 39, 285–294 CrossRef Medline
20. Richter, M. F., Duménil, G., Uze, G., Fellous, M., and Pellegrini, S. (1998) Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon / receptor component IFNAR1. J. Biol. Chem. 273, 24723–24729 CrossRef Medline
21. Colamonici, O. R., Uyttendaele, H., Domanski, P., Yan, H., and Krolewski, J. J. (1994) p135tyk2, an interferon--activated tyrosine kinase, is physically associated with an interferon-alpha receptor. J. Biol. Chem. 269, 3518 –3522 Medline
22. Domanski, P., Fish, E., Nadeau, O. W., Witte, M., Platanias, L. C., Yan, H., Krolewski, J., Pitha, P., and Colamonici, O. R. (1997) A region of the subunit of the interferon receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state. J. Biol. Chem. 272, 26388 –26393 CrossRef Medline
23. Stark, G. R., and Darnell, J. E., Jr. (2012) The JAK-STAT pathway at twenty. Immunity 36, 503–514 CrossRef Medline
24. Platanias, L. C. (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375–386 CrossRef Medline
25. Li, T., Niu, X., Zhang, X., Wang, S., and Liu, Z. (2017) Recombinant human IFN-2b response promotes vaginal epithelial cells defense against Candida albicans. Front. Microbiol. 8, 697 CrossRef Medline
26. Fung, K. Y., Mangan, N. E., Cumming, H., Horvat, J. C., Mayall, J. R., Stifter, S. A., De Weerd, N., Roisman, L. C., Rossjohn, J., Robertson, S. A., Schjen-ken, J. E., Parker, B., Gargett, C. E., Nguyen, H. P., Carr, D. J., Hansbro, P. M., and Hertzog, P. J. (2013) Interferon- protects the female reproductive tract from viral and bacterial infection. Science 339, 1088 –1092 CrossRef Medline
27. Jones, M., Davidson, A., Hibbert, L., Gruenwald, P., Schlaak, J., Ball, S., Foster, G. R., and Jacobs, M. (2005) Dengue virus inhibits interferon signaling by reducing STAT2 expression. J. Virol. 79, 5414 –5420 CrossRef Medline
28. Grant, A., Ponia, S. S., Tripathi, S., Balasubramaniam, V., Miorin, L., Sourisseau, M., Schwarz, M. C., Sanchez-Seco, M. P., Evans, M. J., Best, S. M., and Garcia-Sastre, A. (2016) Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe 19, 882– 890 CrossRef Medline
29. Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A., and McFadden, G. (2003) Poxviruses and immune evasion. Annu. Rev. Immunol. 21, 377– 423 CrossRef Medline
30. Symons, J. A., Alcamí, A., and Smith, G. L. (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551–560 CrossRef Medline
31. Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A., and Buller, R. M. (1995) Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon transmembrane signaling. J. Biol. Chem. 270, 15974 –15978 CrossRef Medline
32. Huang, J., Smirnov, S. V., Lewis-Antes, A., Balan, M., Li, W., Tang, S., Silke, G. V., Pütz, M. M., Smith, G. L., and Kotenko, S. V. (2007) Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc. Natl. Acad. Sci. U.S.A. 104, 9822–9827 CrossRef Medline
33. Pestka, S., Krause, C. D., Sarkar, D., Walter, M. R., Shi, Y., and Fisher, P. B. (2004) Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22, 929 –979 CrossRef Medline
34. Pestka, S., Krause, C. D., and Walter, M. R. (2004) Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8 –32 CrossRef Medline
35. Walter, M. R. (2004) Structural analysis of IL-10 and type I interferon family members and their complexes with receptor. Adv. Protein Chem. 68, 171–223 CrossRef Medline
36. LaFleur, D. W., Nardelli, B., Tsareva, T., Mather, D., Feng, P., Semenuk, M., Taylor, K., Buergin, M., Chinchilla, D., Roshke, V., Chen, G., Ruben, S. M., Pitha, P. M., Coleman, T. A., and Moore, P. A. (2001) Interferon-, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 276, 39765–39771 CrossRef Medline
37. Hardy, M. P., Owczarek, C. M., Jermiin, L. S., Ejdebäck, M., and Hertzog, P. J. (2004) Characterization of the type I interferon locus and identification of novel genes. Genomics 84, 331–345 CrossRef Medline
38. Garcia-Minambres, A., Eid, S. G., Mangan, N. E., Pade, C., Lim, S. S., Matthews, A. Y., de Weerd, N. A., Hertzog, P. J., and Mak, J. (2017) Interferon promotes HIV restriction at multiple steps of viral replication. Immunol. Cell Biol. 95, 478 – 483 CrossRef Medline
39. Tasker, C., Subbian, S., Gao, P., Couret, J., Levine, C., Ghanny, S., Sotero-poulos, P., Zhao, X., Landau, N., Lu, W., and Chang, T. L. (2016) IFN- protects primary macrophages against HIV infection. JCI insight 1, e88255 Medline
40. Abdulhaqq, S. A., Zorrilla, C., Kang, G., Yin, X., Tamayo, V., Seaton, K. E., Joseph, J., Garced, S., Tomaras, G. D., Linn, K. A., Foulkes, A. S., Azzoni, L., VerMilyea, M., Coutifaris, C., Kossenkov, A. V., et al. (2016) HIV-1-negative female sex workers sustain high cervical IFN-, low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunol. 9, 1027–1038 CrossRef Medline
41. Reiser, J., Hurst, J., Voges, M., Krauss, P., Münch, P., Iftner, T., and Stuben-rauch, F. (2011) High-risk human papillomaviruses repress constitutive interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 85, 11372–11380 CrossRef Medline
42. Kuruganti, S., Accavitti-Loper, M. A., and Walter, M. R. (2014) Production and characterization of thirteen human type-I interferon- subtypes. Protein Expr. Purif. 103, 75– 83 CrossRef Medline
43. Yoon, S. I., and Walter, M. R. (2007) Identification and characterization of a 1 frameshift observed during the expression of Epstein-Barr virus IL-10 in Escherichia coli. Protein Expr. Purif. 53, 132–137 CrossRef Medline
44. Radhakrishnan, R., Walter, L. J., Hruza, A., Reichert, P., Trotta, P. P., Nagabhushan, T. L., and Walter, M. R. (1996) Zinc mediated dimer of human interferon- 2b revealed by X-ray crystallography. Structure 4, 1453–1463 CrossRef Medline
45. Deshpande, A., Putcha, B. D., Kuruganti, S., and Walter, M. R. (2013) Kinetic analysis of cytokine-mediated receptor assembly using engineered FC heterodimers. Protein Sci. 22, 1100 –1108 CrossRef Medline
46. Thomas, C., Moraga, I., Levin, D., Krutzik, P. O., Podoplelova, Y., Trejo, A., Lee, C., Yarden, G., Vleck, S. E., Glenn, J. S., Nolan, G. P., Piehler, J., Schreiber, G., and Garcia, K. C. (2011) Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146, 621– 632 CrossRef Medline
47. Piehler, J., and Schreiber, G. (1999) Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFN2. J. Mol. Biol. 289, 57– 67 CrossRef Medline
48. Couret, J., Tasker, C., Kim, J., Sihvonen, T., Fruitwala, S., Quayle, A. J., Lespinasse, P., Heller, D. S., and Chang, T. L. (2017) Differential regulation of IFN, IFN, and IFN gene expression in human cervical epithelial cells. Cell Biosci. 7, 57 Medline
49. Jaks, E., Gavutis, M., Uzé, G., Martal, J., and Piehler, J. (2007) Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 366, 525–539 CrossRef Medline
50. Lavoie, T. B., Kalie, E., Crisafulli-Cabatu, S., Abramovich, R., DiGioia, G., Moolchan, K., Pestka, S., and Schreiber, G. (2011) Binding and activity of all human interferon subtypes. Cytokine 56, 282–289 CrossRef Medline
51. Jaitin, D. A., Roisman, L. C., Jaks, E., Gavutis, M., Piehler, J., Van der Heyden, J., Uze, G., and Schreiber, G. (2006) Inquiring into the differential action of interferons (IFNs): an IFN-2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-. Mol. Cell. Biol. 26, 1888 –1897 CrossRef Medline
52. Stifter, S. A., Matthews, A. Y., Mangan, N. E., Fung, K. Y., Drew, A., Tate, M. D., Soares da Costa, T. P., Hampsey, D., Mayall, J., Hansbro, P. M., Garcia Minambres, A., Eid, S. G., Mak, J., Scoble, J., Lovrecz, G., deWeerd, N. A., and Hertzog, P. J. (2018) Defining the distinct, intrinsic properties of the novel type I interferon, IFN. J. Biol. Chem. 293, 3168 –3179 CrossRef Medline
53. Samarajiwa, S. A., Mangan, N. E., Hardy, M. P., Najdovska, M., Dubach, D., Braniff, S. J., Owczarek, C. M., and Hertzog, P. J. (2014) Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock. J. Immunol. 192, 4425– 4435 CrossRef Medline
54. Myszka, D. G. (1999) Improving biosensor analysis. J. Mol. Recognit. 12, 279 –284 CrossRef Medline